Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Type II JAK2 Inhibitor NVP-CHZ868 is Active in Vitro and in Vivo Against JAK2-Dependent B-cell Acute Lymphoblastic Leukemias


ABSTRACT: Gene expression profiling was performed to define transcriptional programs associated with response to type II JAK2 inhibitor NVP-CHZ868 alone or in combination with dexamethasone in vitro and in vivo. MHH-CALL4 cells harboring a CRLF2 rearrangement and JAK2 I682F mutation were treated with vehicle, CHZ868, dexamethasone, or CHZ868 + dexamethasone combination for 12 hours in triplicate. RNA was then extracted for hybridization on Affymetrix microarrays. CRLF2+ patient-derived xenografts (05-412, 05-440, and 05-537) were treated in vivo for 3 days with vehicle, CHZ868, dexamethasone, or CHZ868 + dexmathasone combination for 3 days and then sacrificed. Transcriptional profiling was performed on unselected splenocytes from these animals.

ORGANISM(S): Homo sapiens

SUBMITTER: Loretta Li 

PROVIDER: E-GEOD-61696 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2020-05-28 | GSE132486 | GEO
2018-05-31 | GSE102533 | GEO
2015-06-18 | GSE61696 | GEO
2013-09-28 | E-GEOD-51241 | biostudies-arrayexpress
2013-09-28 | GSE51241 | GEO
2021-05-18 | GSE174578 | GEO
2019-08-13 | PXD013977 | Pride
2010-07-08 | E-GEOD-22404 | biostudies-arrayexpress
2020-08-20 | PXD006921 | Pride
2010-06-19 | GSE22404 | GEO